Reply to: “Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials”

I want to thank Dr Rieder1 for drawing attention to the challenges faced by brodalumab. I agree with nearly all the points made, although I hope Dr Rieder's prediction that the Risk Evaluation and Mitigation Strategies (REMS) program will doom this drug prove to be untrue.